Alnylam Pharmaceuticals (ALNY) to Release Earnings on Thursday

Alnylam Pharmaceuticals (NASDAQ:ALNY) is anticipated to issue its quarterly earnings data before the market opens on Thursday, February 13th. Analysts expect the company to announce earnings of ($0.62) per share and revenue of $580.62 million for the quarter. Persons interested in registering for the company’s earnings conference call can do so using this link.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY stock opened at $274.06 on Tuesday. The firm has a market capitalization of $35.35 billion, a price-to-earnings ratio of -104.60 and a beta of 0.35. The company has a 50 day moving average price of $253.20 and a 200 day moving average price of $262.73. Alnylam Pharmaceuticals has a one year low of $141.98 and a one year high of $304.39. The company has a debt-to-equity ratio of 31.64, a quick ratio of 2.69 and a current ratio of 2.75.

Insider Activity

In other Alnylam Pharmaceuticals news, EVP Tolga Tanguler sold 1,469 shares of the business’s stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total transaction of $368,689.62. Following the completion of the sale, the executive vice president now directly owns 13,191 shares of the company’s stock, valued at approximately $3,310,677.18. The trade was a 10.02 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CMO Pushkal Garg sold 52,592 shares of the firm’s stock in a transaction dated Monday, January 27th. The shares were sold at an average price of $285.00, for a total transaction of $14,988,720.00. Following the completion of the transaction, the chief marketing officer now directly owns 11,989 shares in the company, valued at $3,416,865. This trade represents a 81.44 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 73,964 shares of company stock worth $20,622,925. Company insiders own 1.50% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. Sanford C. Bernstein decreased their target price on Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating for the company in a research report on Tuesday, January 7th. Bank of America upped their target price on Alnylam Pharmaceuticals from $307.00 to $314.00 and gave the company a “buy” rating in a research report on Monday, October 14th. HC Wainwright reissued a “buy” rating and set a $400.00 price target on shares of Alnylam Pharmaceuticals in a research report on Monday, January 13th. Barclays boosted their price target on Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the company an “overweight” rating in a report on Friday, November 1st. Finally, StockNews.com downgraded shares of Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, January 9th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and nineteen have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $298.61.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.